Reports Q1 revenue $12.73B, consensus $12.72B. “Lilly had a solid start to the year, with 45% year-over-year revenue growth driven by strong sales of Mounjaro and Zepbound,” said David Ricks, Lilly chair and CEO. “Our pipeline continued to deliver across key therapeutic areas, with product approvals in oncology and immunology, and the exciting success of our oral incretin, orforglipron, in the first of seven late-stage studies in diabetes and obesity. To support global demand for our newest medicines, we’re accelerating our manufacturing investments, as underscored by our recent announcement to build four new facilities.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Options Volatility and Implied Earnings Moves Today, May 01, 2025
- Is Eli Lilly’s $850 Billion Valuation Too Expensive Ahead of Earnings?
- Notable companies reporting before tomorrow’s open
- WW International Stock (WW) Doubles on Eli Lilly Weight-Loss Drug Partnership
- Creyon Bio receives $13M upfront in collaboration with Eli Lilly